阿魏酸哌嗪联合厄贝沙坦治疗糖尿病肾病的临床疗效及安全性探讨

Clinical Efficacy and Safety of Piperazine Ferulate Combined with Irbesartan in the Treatment of Diabetic Nephropathy

目的:观察阿魏酸哌嗪联合厄贝沙坦治疗糖尿病肾病的临床疗效及安全性。方法:选择我院收治糖尿病肾病患者60例为研究对象,随机分为试验组(n=30,在基础治疗上加以阿魏酸哌嗪+厄尔沙坦治疗)和对照组(n=30,在基础治疗上加以厄贝沙坦治疗),以血肌酐(Scr)、尿素氮(BUN)、尿微量白蛋白比较其肾功能,同时,比较其平均动脉压(MAP)、红细胞压积和不良反应。结果:治疗后,两组肾功能指标(Scr、BUN、尿微量白蛋白)均显著降低(P<0.05),且试验组上述治疗后的肾功能指标均低于对照组(P<0.05);治疗后,两组MAP及红细胞压积均显著降低(P<0.05),且试验组治疗后的MAP及红细胞压积均低于对照组(P<0.05);试验组23.33%的不良反应发生率与对照组的20.00%比较,差异无统计学意义。结论:阿魏酸哌嗪+厄贝沙坦治疗糖尿病肾病可有效改善肾功能,降低血液黏稠度和血压,安全性可靠。

Objective:To observe the clinical efficacy and safety of piperazine ferulate combined with irbesartan in the treatment of diabetic nephropathy.Methods:60 patients with diabetic nephropathy were enrolled in our hospital.The patients were randomly divided into experimental groups(n=30.Piperazine ferulic acid+Earl was given to the basic treatment.Satan treatment)and control group(n=30,irbesartan in basic treatment),blood creatinine(Scr),urea nitrogen(BUN),urine microalbumin compared with renal function,while comparing the average Arterial pressure(MAP),hematocrit,and adverse reactions.Results:After treatment,the renal function indexes(Scr,BUN,urinary microalbumin)were significantly lower(P<0.05),and the renal function indexes of the experimental group were lower than those of the control group(P<0.05).After the two groups,MAP and hematocrit were significantly lower(P<0.05),and the MAP and hematocrit of the experimental group were lower than those of the control group(P<0.05).The incidence of adverse reactions was 23.33%in the experimental group.There was no statistically significant difference in the 20.00%comparison of the control group.Conclusions:Piperazine ferulic acid+irbesartan can effectively improve renal function,reduce blood viscosity and blood pressure,and is safe and reliable.